Real-world experience of fingolimod in patients with multiple sclerosis (MS Fine): An observational study in the UK

BACKGROUND: Fingolimod is approved for the treatment of highly active relapsing–remitting multiple sclerosis in Europe. There is limited information on its effectiveness and safety in clinical practice within the UK. OBJECTIVE: To evaluate retrospectively the effectiveness and safety of fingolimod i...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazibrada, Gordon, Sharples, Charlotte, Perfect, Ines
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178378/
https://www.ncbi.nlm.nih.gov/pubmed/30327723
http://dx.doi.org/10.1177/2055217318801638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178378/
https://www.ncbi.nlm.nih.gov/pubmed/30327723
http://dx.doi.org/10.1177/2055217318801638

Ejemplares similares